Identifying biomarkers to predict chemotherapy response in gastric cancer
Postgenome-based Systemic Discovery of Strong Biomarkers Predict Gastric Cancer Chemotherapy Response
This study is trying to find specific markers in blood and tissue samples from gastric cancer patients to see if they can predict how well those patients will respond to chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Kyungpook National University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Daegu) |
| Trial ID | NCT03253107 on ClinicalTrials.gov |
What this trial studies
This study aims to discover and validate biomarkers that can predict how patients with gastric cancer will respond to chemotherapy. It involves analyzing the expression levels of mRNA and miRNA in gastric cancer tissues and blood samples using next-generation sequencing techniques. The study will also validate these findings through quantitative reverse transcription PCR (qRT-PCR) across multiple independent cohorts. By combining biological biomarkers with clinical factors, the research seeks to develop a predictive model for chemotherapy response in gastric cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are new gastric cancer patients who are scheduled to start their first cycle of chemotherapy.
Not a fit: Patients with other cancers or those who refuse to participate in the study may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective chemotherapy treatments for gastric cancer patients.
How similar studies have performed: Other studies have shown promise in using biomarkers to predict chemotherapy responses in various cancers, suggesting that this approach may be effective for gastric cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * new gastric cancer patients who has scheduled to start 1st cycle of chemotherapy * patients who agreed this study and voluntarily assigned the informed consents. Exclusion Criteria: * patients who refused the study. * patients who have other cancers * heavy alcoholics
Where this trial is running
Daegu
- Kyungpook National University Medical Canter — Daegu, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Su Youn Nam, MD, PhD — Kyungpook National University Medical Center
- Study coordinator: Su Youn Nam, MD, PhD
- Email: nam20131114@gmail.com
- Phone: 82-53-200-2610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.